Our Take
This is vendor content masquerading as industry analysis—Upperton built the argument around their own operating model, not a field-wide benchmark or independent finding.
Why it matters
Biotech sponsors do face real CDMO handoff risk, but lack frameworks to evaluate it before partnership. The piece identifies genuine friction points (multi-site fragmentation, siloed project management, knowledge loss at transitions) that matter to program timelines and regulatory compliance.
Do this week
Biotech sponsor: audit your current or prospective CDMO on team continuity across phases (preformulation through GMP) and ask whether the same project lead owns the program end-to-end, not just checks a box.
CDMO risk emerges from operational design, not chance
Contract development and manufacturing organizations vary widely in how they manage the inherent unpredictability of drug development. Some deliberately architect their operations around risk reduction; others inadvertently amplify uncertainty through fragmented teams, multi-site handoffs, and siloed project management.
The article identifies three structural sources of risk accumulation: (1) Multiple handoffs across disconnected sites and teams, each a vulnerability point for miscommunication and knowledge loss. (2) Project management treated as administrative overhead rather than integrated scientific delivery, leaving managers unable to foresee technical risks early. (3) Poor communication workflows between CDMO and sponsor, allowing "unknown unknowns" to compound before surfacing.
By contrast, CDMOs that mitigate risk operationally embed continuity into their design: same program team from day one through commercial manufacturing, one-site facilities designed for linear material and personnel flow, and cross-functional collaboration that flags uncertainties early rather than conceals them under schedule pressure.
Team continuity and operational transparency are real cost variables
Biotech sponsors operate under tight budgets and lean internal teams, making external partner reliability a material business variable. A late batch, unexpected deviation, or missed milestone triggered by CDMO communication breakdown or knowledge loss can delay regulatory submissions by months and consume contingency budget.
The piece correctly flags that risk is not simply technical or regulatory—it is shaped by how teams are organized and whether information flows transparently between sponsor and manufacturer. Sponsors cannot eliminate this risk, but they can evaluate a CDMO's structural capacity to surface and manage it before signing.
However, the article does not measure this objectively. No benchmarks compare program delays, deviation rates, or cost overruns across single-site versus multi-site CDMOs. No sponsor data validates whether one-site operations actually deliver faster timelines or fewer surprises. The risk factors identified are plausible, but the evidence is structural description, not outcome data.
Evaluate CDMO design before commitment
Sponsor teams should assess a prospective CDMO on three concrete criteria: (1) Ask who the core program team is and whether it includes the same technical and project lead from early formulation work through tech transfer and GMP manufacturing. If the company reorganizes ownership at each phase, you inherit handoff risk. (2) Understand the physical and reporting structure. Multi-building sites with separate preformulation, analytical, and manufacturing teams introduce communication latency. (3) Request a specimen communication plan and escalation path—how often do you hear from them, through which channels, and who owns resolution of technical issues.
Single-site operations are not guaranteed to perform better—execution culture and individual leadership matter as much as architecture. But structural integration (one team, one site, continuous ownership) makes sustained miscommunication harder to hide. Use it as a filter, not a guarantee.